Thylacine Bio

United States
Headland, Alabama, United States, 33141

Company profile

Thylacine Bio company profile

Thylacine Bio engages in developing a peptide platform for pandemic preparedness. The platform can be rapidly tuned and applied to new and existing pathogens. It targets conserved regions less susceptible to mutation, unlocking efficacy across variants. The resulting antivirals are potent, self-administered, and easily distributed.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0+
Founded
2021-01-01, Year

Headquarters

Postal code
33141
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
2
Total equity funding
$476,000
Last funding
Seed / $476,000 / 2023-01-19
Last equity funding
Seed / $476,000
Founders
2
Articles
1

Founders and investors

Founders

Anne MosconaMatteo Porotto